氟哌噻吨美利曲辛联合SIT对变应性鼻炎伴焦虑(抑郁)状态患者的疗效分析  

Clinical observation of flupentixol and melitracen combined with specific immunotherapy for treatment of allergic rhinitis patients with anxiety and depression

作　　者：易烛光[1] 杨秀海[1] 任娟娟[1] 彭维晖[1] 梁秋林[1] 

机构地区：[1]贵州省人民医院耳鼻咽喉头颈外科,贵阳550002

出　　处：《临床耳鼻咽喉头颈外科杂志》2017年第1期34-37,42,共5页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：基金项目:贵州省科学技术厅[No:黔科合SY(2010)3123]

摘　　要：目的:探讨氟哌噻吨美利曲辛联合特异性免疫治疗(SIT)治疗变应性鼻炎(AR)伴焦虑(抑郁)状态患者的疗效。方法:选取2014-10-2015-09期间收治的99例中重度持续AR伴焦虑及抑郁患者,随机分成2组(实验组45例,对照组44例),所有患者给予标准化尘螨变应原疫苗SIT,疗程1年,实验组在此基础上再予氟哌噻吨美利曲辛口服(1片/d),疗程4个月。观察治疗前、治疗4个月和1年后的鼻部症状评分、迷你鼻结膜炎生活质量问卷(MiniRQLQ)、用药评分、焦虑状态量表(SAS)、抑郁状态量表(SDS)评分及临床疗效。同时收集2组发生的不良反应。结果:与治疗前比较,治疗4个月和1年后2组鼻部症状评分、MiniRQLQ各项评分、用药评分、SAS及SDS积分均降低,均差异有统计学意义(P<0.05);与对照组比较,在治疗4个月后实验组鼻部症状评分、MiniRQLQ各项评分、用药评分、SAS和SDS评分以及在治疗1年后的用药评分、SAS和SDS评分均降低(P<0.05);在治疗1年后,2组鼻部症状评分和MiniRQLQ各项评分、临床总有效率差异无统计学意义(P>0.05)。治疗4个月后,实验组总有效率为84.4%,对照组为56.8%;治疗1年后,实验组显效率为57.8%,对照组为22.7%;均差异有统计学意义(均P<0.05);治疗过程中共出现13例轻度不良反应,实验组8例(17.7%)和对照组5例(11.4%),差异无统计学意义(P>0.05)。结论:对于中重度AR伴焦虑抑郁状态患者,应用氟哌噻吨美利曲辛联合SIT能够进一步改善其临床症状、生活质量和精神状态,可提高临床疗效且安全可靠。Objective：To explore the clinical effects of Flupentixol/Melitracencombined with specific immunotherapy in allergic rhinitis patients with anxiety and depression.Method：Totally ninety-nine moderate-to-severepersistent allergic rhinitis patients with anxiety and depression from October 2014 to Sepetember 2015 were randomly divided into two groups：45 patients in experimental group（Flupentixol/Melitracen 10.5mg,QD,treatment last 4 months）and 44 patients in control group.All patients were treated with specific immunotherapy for 1 years.The nasal symptoms score,mini Rhinoconjunctivitis Quality of life questionnaire（MiniRQLQ）,Medication score,SAS and SDS score and the clinical curative effect were observed before treatment,after 4 months or one year treatment.The drug reactions were also recorded.Result：The VAS scores,MiniRQLQ scores,medication scores,SAS and SDS scores of patients in two groups who were treated after 4 months and 1 year were significantly reduced than that of patients before treatment.The differences were statistically significant（P〈0.05）.Compared with the control group,nasal symptom scores,MiniRQLQ scores,medication scores,SAS and SDS scores in experimental group were decreased after 4 month or 1 year treatment（P〈0.05）.After 4 months of treatment,the total effective rate of the experimental group was 84.4%,while the control group was 56.8%.After 1 years of treatment,the experimental group excellence rate was 57.8%,while the control group was 22.7%.The differences were statistically significant（P〈0.05）.During the course of treatment,there were thirteen cases of mild adverse reactionsin experimental group（17.7%）and control group（11.4%）.There was no significant differences（P〉0.05）.Conclusion：Flupentixol and melitracen combined with specific immunotherapy could sifnificantlly relieve clinical symptom,quality of life and mental depression.is a safe and reliable therapeutic regimen for further improving clinical symptoms,quality of life,mental statusand the

关 键 词：鼻炎 变应性 氟哌噻吨美利曲辛 特异性免疫治疗 焦虑 抑郁 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]